Case 24: Progressive Glioma

Ian Law; Jonathan F. Carlsen; Benedikte Hasselbalch

doi:10.1007/978-3-030-83598-9_24

Case 24: Progressive Glioma

Ian Law, Jonathan F. Carlsen, Benedikte Hasselbalch

Abstract

The use of O-(2-[18F]fluoroethyl)-l-tyrosine ([18F]FET) PET permits a more sensitive assessment of metabolically active tumor, treatment failure, and distant non-contrast-enhancing progression in this patient with anaplastic oligodendroglioma, WHO grade III, where progression on MRI was challenged because of changing patterns of speckled new and dissolving old non-measurable contrast enhancement.

Original language	English
Title of host publication	Clinical Nuclear Medicine in Neurology : An Atlas of Challenging Cases
Editors	Andrea Varrone, Silvia Morbelli, Valentina Garibotto
Number of pages	5
Place of Publication	Cham
Publisher	Springer International Publishing
Publication date	2022
Pages	119-123
ISBN (Print)	978-3-030-83598-9
DOIs	https://doi.org/10.1007/978-3-030-83598-9_24
Publication status	Published - 2022

Access to Document

10.1007/978-3-030-83598-9_24

Cite this

Case 24: Progressive Glioma. / Law, Ian ; Carlsen, Jonathan F.; Hasselbalch, Benedikte.
Clinical Nuclear Medicine in Neurology: An Atlas of Challenging Cases. ed. / Andrea Varrone; Silvia Morbelli; Valentina Garibotto. Cham: Springer International Publishing, 2022. p. 119-123.

Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Research › peer-review

@inbook{443d68b5612b445fbcadeafad2518c51,

title = "Case 24: Progressive Glioma",

abstract = "The use of O-(2-[18F]fluoroethyl)-l-tyrosine ([18F]FET) PET permits a more sensitive assessment of metabolically active tumor, treatment failure, and distant non-contrast-enhancing progression in this patient with anaplastic oligodendroglioma, WHO grade III, where progression on MRI was challenged because of changing patterns of speckled new and dissolving old non-measurable contrast enhancement.",

author = "Ian Law and Carlsen, {Jonathan F.} and Benedikte Hasselbalch",

year = "2022",

doi = "10.1007/978-3-030-83598-9_24",

language = "English",

isbn = "978-3-030-83598-9",

pages = "119--123",

editor = "Andrea Varrone and Silvia Morbelli and Valentina Garibotto",

booktitle = "Clinical Nuclear Medicine in Neurology",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Case 24: Progressive Glioma

AU - Law, Ian

AU - Carlsen, Jonathan F.

AU - Hasselbalch, Benedikte

PY - 2022

Y1 - 2022

N2 - The use of O-(2-[18F]fluoroethyl)-l-tyrosine ([18F]FET) PET permits a more sensitive assessment of metabolically active tumor, treatment failure, and distant non-contrast-enhancing progression in this patient with anaplastic oligodendroglioma, WHO grade III, where progression on MRI was challenged because of changing patterns of speckled new and dissolving old non-measurable contrast enhancement.

AB - The use of O-(2-[18F]fluoroethyl)-l-tyrosine ([18F]FET) PET permits a more sensitive assessment of metabolically active tumor, treatment failure, and distant non-contrast-enhancing progression in this patient with anaplastic oligodendroglioma, WHO grade III, where progression on MRI was challenged because of changing patterns of speckled new and dissolving old non-measurable contrast enhancement.

UR - http://www.scopus.com/inward/record.url?scp=85170995795&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-83598-9_24

DO - 10.1007/978-3-030-83598-9_24

M3 - Book chapter

SN - 978-3-030-83598-9

SP - 119

EP - 123

BT - Clinical Nuclear Medicine in Neurology

A2 - Varrone, Andrea

A2 - Morbelli, Silvia

A2 - Garibotto, Valentina

PB - Springer International Publishing

CY - Cham

ER -

Case 24: Progressive Glioma

Abstract

Access to Document

Other files and links

Fingerprint

Cite this